BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17035397)

  • 1. Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
    Anderson WF; Pfeiffer RM; Dores GM; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1899-905. PubMed ID: 17035397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma.
    Anderson WF; Chu KC; Chang S; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1128-35. PubMed ID: 15247123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
    Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK
    Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
    Anderson WF; Chen BE; Jatoi I; Rosenberg PS
    Breast Cancer Res Treat; 2006 Nov; 100(1):121-6. PubMed ID: 16685588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute.
    Anderson WF; Devesa SS
    Cancer; 2005 Oct; 104(8):1733-41. PubMed ID: 16138363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic excess of estrogen receptor-positive breast cancer.
    Benz CC; Clarke CA; Moore DH
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1523-7. PubMed ID: 14693747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S; Gutierrez J; Avisar E
    Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct incidence patterns among in situ and invasive breast carcinomas,with possible etiologic implications.
    Anderson WF; Chu KC; Devesa SS
    Breast Cancer Res Treat; 2004 Nov; 88(2):149-59. PubMed ID: 15564798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study.
    Nyante SJ; Dallal CM; Gierach GL; Park Y; Hollenbeck AR; Brinton LA
    Am J Epidemiol; 2013 Aug; 178(3):359-71. PubMed ID: 23899816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.
    Li CI; Malone KE; Daling JR
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):601-7. PubMed ID: 12101106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii.
    Fong M; Henson DE; Devesa SS; Anderson WF
    Breast Cancer Res Treat; 2006 May; 97(1):57-65. PubMed ID: 16322891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution.
    Intra M; Rotmensz N; Viale G; Mariani L; Bonanni B; Mastropasqua MG; Galimberti V; Gennari R; Veronesi P; Colleoni M; Tousimis E; Galli A; Goldhirsch A; Veronesi U
    Cancer; 2004 Sep; 101(5):905-12. PubMed ID: 15329896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
    Jemal A; Ward E; Thun MJ
    Breast Cancer Res; 2007; 9(3):R28. PubMed ID: 17477859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing incidence rate of invasive lobular breast carcinoma among older women.
    Li CI; Anderson BO; Porter P; Holt SK; Daling JR; Moe RE
    Cancer; 2000 Jun; 88(11):2561-9. PubMed ID: 10861434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models.
    Reimers LL; Anderson WF; Rosenberg PS; Henson DE; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):792-800. PubMed ID: 19258470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia.
    Albasri A; Hussainy AS; Sundkji I; Alhujaily A
    Saudi Med J; 2014 Dec; 35(12):1489-93. PubMed ID: 25491214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.
    Swede H; Gregorio DI; Tannenbaum SH; Brockmeyer JA; Ambrosone C; Wilson LL; Pensa MA; Gonsalves L; Stevens RG; Runowicz CD
    Clin Breast Cancer; 2011 Oct; 11(5):332-41. PubMed ID: 21729670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
    Kolár Z; Murray PG; Zapletalová J
    Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.